Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Net Income: 2009-2025

Historic Net Income for Myriad Genetics (MYGN) over the last 16 years, with Sep 2025 value amounting to -$27.4 million.

  • Myriad Genetics' Net Income fell 23.98% to -$27.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$400.5 million, marking a year-over-year decrease of 245.26%. This contributed to the annual value of -$127.3 million for FY2024, which is 51.65% up from last year.
  • As of Q3 2025, Myriad Genetics' Net Income stood at -$27.4 million, which was up 91.71% from -$330.5 million recorded in Q2 2025.
  • In the past 5 years, Myriad Genetics' Net Income registered a high of $24.6 million during Q3 2021, and its lowest value of -$330.5 million during Q2 2025.
  • Its 3-year average for Net Income is -$68.1 million, with a median of -$36.7 million in 2024.
  • Its Net Income has fluctuated over the past 5 years, first soared by 261.84% in 2021, then slumped by 800.54% in 2025.
  • Quarterly analysis of 5 years shows Myriad Genetics' Net Income stood at -$7.6 million in 2021, then plummeted by 456.58% to -$42.3 million in 2022, then grew by 26.24% to -$31.2 million in 2023, then slumped by 36.22% to -$42.5 million in 2024, then declined by 23.98% to -$27.4 million in 2025.
  • Its Net Income stands at -$27.4 million for Q3 2025, versus -$330.5 million for Q2 2025 and -$100,000 for Q1 2025.